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The placement of an implantable cardioverter defibrillator (ICD) has become routine prac-
tice to protect high risk patients from sudden cardiac death. However, implantation-related
myocardial micro-damage and its relation to different implantation strategies are poorly
characterized.
Methods
A total of 194 ICD recipients (64±12 years, 83%male, 95% primary prevention of sudden
cardiac death, 35% cardiac resynchronization therapy) were randomly assigned to one of
three implantation strategies: (1) ICD implantation without any defibrillation threshold (DFT)
testing, (2) estimation of the DFT without arrhythmia induction (modified “upper limit of vul-
nerability (ULV) testing”) or (3) traditional safety margin testing including ventricular arrhyth-
mia induction. High-sensitive Troponin T (hsTnT) levels were determined prior to the
implantation and 6 hours after.
Results
All three groups showed a postoperative increase of hsTnT. The mean delta was 0.031±0.032
ng/ml for patients without DFT testing, 0.080±0.067 ng/ml for the modified ULV-testing and
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0.064±0.056 ng/ml for patients with traditional safety margin testing. Delta hsTnT was signifi-
cantly larger in both of the groups with intraoperative ICD testing compared to the non-testing
strategy (p0.001 each). There was no statistical difference in delta hsTnT between the two
groups with intraoperative ICD testing (p = 0.179).
Conclusion
High-sensitive Troponin T release during ICD implantation is significantly higher in patients
with intraoperative ICD testing using shock applications compared to those without testing.
Shock applications, with or without arrhythmia induction, did not result in a significantly dif-





In high-risk patients the implantation of an implantable cardioverter defibrillator (ICD) is the
treatment of choice for primary and secondary prevention of sudden cardiac death. To confirm
the proper function of the ICD system, intraoperative defibrillation threshold (DFT) testing is
widely used [1–2]. Typically, ventricular fibrillation is induced twice by the application of
shocks on the T-wave. Termination of the induced arrhythmia with 10 Joule (J) below the max-
imum output energy of the device is considered to be an adequate safety margin.
However, in recent years the need for a traditional safety margin testing has been questioned
[2–4]. One reason for this is the suspicion that ventricular fibrillation and ICD shocks, inherent
to the safety margin testing, may cause myocardial damage [5–7]. Several non-randomized
studies have shown an elevation of cardiac enzymes measured after ICD implantation with
intraoperative DFT testing or after pre-hospital-discharge testing [7–9]. However, the reason
for the elevation of cardiac enzymes after DFT testing and also after spontaneous appropriate
ICD shocks remains unclear [10–11]. A potential cause of myocardial micro-damage might be
that ventricular fibrillation causes myocardial ischemia and consequently an increase in cardiac
enzyme levels, or the damage might be directly related to the shock itself. Neither the effect of
induced ventricular fibrillation nor the effect of an ICD shock itself on human myocardial tis-
sue have been studied entirely [12]. Therefore, the TropShock trial intends to characterize
changes in levels of cardiac enzymes after different intraoperative ICD testing modes. In partic-
ular, it aims to elucidate whether induced ventricular fibrillation or the ICD shock itself causes
myocardial damage.
Methods
The study protocol was approved by the ethics committee of the Technical University of
Munich as leading ethics committee for the Deutsches Herzzentrum München and Klinikum
Landshut (approval number 2869/10; date 07/30/2010), as well as approved by the ethics com-
mittee of Freiburg: Albert-Ludwigs-Universität Freiburg, approval number 271/10; date 08/31/
2010) and complied with conditions laid out by the declaration of Helsinki. All patients gave
their written informed consent prior to study inclusion.
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Study population
The TropShock trial was a prospective, randomized, multi-center trial, which aimed at patients
receiving the de-novo implantation of ICD therapy for the primary or secondary prevention of
sudden cardiac death; including patients with cardiac resynchronization therapy (CRT)
(ClinicalTrials.gov identifier: NCT01230086; for logistic reasons the trial was registered after
the recruitment began; the authors confirm that all ongoing and related trials for this interven-
tion are registered). Inclusion criteria were the left-sided placement of an ICD capable of deliv-
ering at least 35 J for cardioversions or defibrillations and the intention to place an active
fixation defibrillation lead in the apical region of the right ventricle. Patients with any of the fol-
lowing criteria were excluded:
- myocardial infarction, percutaneous coronary intervention, resuscitation or cardiac surgery
four weeks prior to ICD implantation,
- coronary artery disease with an indication of revascularization,
- presence of intra-cardiac thrombi,
- contraindication for the induction of ventricular fibrillation or the application of shocks,
- atypical placement of the ventricular lead requiring defibrillation testing,
- right-sided placement of the ICD,
- planned external cardioversion of atrial tachyarrhythmias,
- lead revision or lead extraction,
- upgrade of an pre-existing ICD to a CRT-ICD,
- ASA (American Society of Anesthesiologists) status4,
- inability to give written informed consent, age<18 years.
Study protocol
Between June 2010 and August 2012 patients were randomly assigned to one of the following
three implantation strategies: (1) implantation only (no arrhythmia induction or shock appli-
cation) (2) implantation with DFT estimation by a modified upper limit of vulnerability testing
(implantation plus shock application) or (3) traditional implantation strategy including the
induction of ventricular tachyarrhythmias with safety margin testing for the DFT. Random
patient allocation was performed by sealed envelopes on a 2:2:1 basis stratified by centre and
by CRT versus non-CRT ICD systems.
Study endpoints
The primary study endpoint was the level of myocardial micro-damage assessed by the delta in
the serum high sensitive Troponin T levels (hsTnT) calculated from the difference between the
level 6 hours after ICD implantation and the preoperative baseline value.
Pre-specified secondary endpoints included the delta in the serum creatinkinase (total and
MB fraction) during the same observational period, and the correlation between the delta
hsTnT levels and the procedure time, the number of intra-operative lead repositionings, the
underlying cardiac disease and the left ventricular ejection fraction.
All endpoints were evaluated according to the intention to treat principle.
ICD Shock Causes Elevation of hs-Troponin T
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Implantation procedure and testing methods
Blood samples were drawn before the implantation procedure to determine the baseline serum
levels of hsTnT (Elecsys high sensitive Troponin T, Roche diagnostics, Rotkreuz, Switzerland),
creatinkinase (total and MB fraction), creatinine and urea. All implantation procedures were
performed under analgosedation with the applied drugs left to the discretion of the respective
physician. Vital parameters were continuously monitored with the aim of maintaining sedation
levels of 3 to 4 according to the Ramsay scale [13] during the whole implantation procedure.
Transvenous ICD implantation followed institutional standards with device placement either
in a left-sided subpectoral or subcutaneous pocket and with the right ventricular lead posi-
tioned in the right ventricular apex. Right atrial and left ventricular leads–where applicable–
were also implanted according to institutional standards. After achieving adequate values for
the sensing and pacing threshold of the leads, the procedure was continued according to the
individual’s randomization assignment.
In patients randomized to “no defibrillation threshold estimation”, the pocket was closed
and the patient left the operation room without further DFT testing.
In patients randomized to “implantation with shock application”, a modified upper limit of
vulnerability testing was performed. For this, three ICD shocks at three different energy levels
were administered to the ascending part of the T wave. The concept of upper limit of vulnera-
bility testing is based on the observed correlation between the individual DFT and an individ-
ual energy amount applied to the vulnerable phase of the repolarization, above which no
arrhythmia can be induced [14]. Modified protocols for the upper limit of vulnerability limit
the number of arrhythmia inductions [15–17] and we further modified the protocol to allow
an estimation of the DFT without inducing ventricular tachyarrhythmias. For this, the energies
applied to the heart during the ascending part of the T-wave were carefully selected to achieve
a DFT which would equal that achieved by 10 J safety margin testing. The energy was calcu-
lated to add up to the same as that which would be delivered cumulatively during traditional 10
J safety margin testing. Finally, energies were adjusted to the different energy levels applicable
to the devices of different manufacturers (Table 1).
For pure study reasons, a shock coinciding with the R-wave would have been sufficient but
potentially unethical. Therefore, the more sophisticated method of the modified upper limit of
Table 1. Cumulative shock energy.





Maximal shock energy of the device (Joule
[J])
35 36 40 41 42
Shock 1 [J] 1+25 1+25 1+30 1+31 1+32
Safety margin testing Shock 2 [J] 1+25 1+25 1+30 1+31 1+32
Σ energy [J] 52 52 62 64 66
Shock 1 [J] 22 22,5 26 27 28
Upper limit of vulnerability
testing
Shock 2 [J] 18 17,5 22 23 22
Shock 3 [J] 12 12,5 14 14 16
Σ energy [J] 52 52,5 62 64 66
Cumulative shock energy applied on the myocardium during safety margin testing or upper limit of vulnerability testing according to randomization and
adjusted to the different energy levels applicable to the devices of different manufacturers.
doi:10.1371/journal.pone.0131570.t001
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vulnerability testing was chosen to provide the patient with some estimation of his/her DFT in
the setting of our clinical study.
In patients randomized to “the implantation of the device followed by traditional 10 J safety
margin testing” ventricular fibrillation was twice induced by a shock on T (1 J) and was termi-
nated by a shock 10 J below the maximal available energy of the respective ICD (Table 1).
For the evaluation of hsTnT (primary endpoint), CK and CK-MB levels, further blood sam-
ples were taken 6 hours after ICD testing. In patients randomized to “no testing at all” the sam-
ples were taken at the same time intervals and the “induction time” was presumed to be one
minute before the start of the intra-cutaneous suture.
Procedure in case of deviations from the test protocol
All investigators were repeatedly educated to adhere strictly to the test protocol and to the ran-
domized group. However, certain specific circumstances that could obviate the strict adherence
to the testing protocol had been anticipated and recommendations for their management had
been given in advance.
In cases in which the apical target region for the right ventricular lead could not be reached
or yielded unsatisfactory results for the lead parameters, the implanter could select other pacing
sites and it was recommended that traditional safety margin testing should be performed. In
the case of ventricular arrhythmia induction during modified upper limit of vulnerability test-
ing, arrhythmia termination had to be attempted at 10 J below the maximal energy provided by
the respective device. The further procedure was then left to the discretion of the implanting
physician. In the case of atrial arrhythmia induction during modified upper limit of vulnerabil-
ity testing or during traditional safety margin testing, the implanters were advised to wait 5–10
minutes for spontaneous conversion to sinus rhythm and as a second step to attempt a phar-
macological cardioversion (both in order to avoid further shocks as far as possible). If atrial
tachyarrhythmias persisted, the implanters were free to decide on an electrical cardioversion at
the end of the procedure. If ventricular fibrillation was not inducible (safety margin testing
group only) the implanters were only allowed to stop the testing procedure after the application
of different coupling intervals for the T-wave shock or the application of a ventricular burst
pacing at 50 Hz.
All deviations from the original ICD test protocol were recorded. The analyses of the pre-
specified endpoints were carried out applying the intention-to-treat principle but an additional
analysis based on per protocol treatment was run.
Statistics
Because there were no published data available on hsTnT release in relation to ICD implanta-
tions, historic data from patients supplied with ICDs in the German Heart Centre were used
for sample size calculation. Data from the most recent 30 patients (the most recent 10 patients
without intraoperative ICD testing, with modified upper limit of vulnerability testing and tradi-
tional safety margin testing, respectively) for which there were available values of hsTnT
levels before and after ICD implantation were analysed. The patients did not differ relevantly
in their baseline characteristics and the following mean delta ± standard deviations in
hsTnT levels were observed: implantation without ICD testing 0.034±0.037 ng/ml (group 1),
modified upper limit of vulnerability testing 0.053±0.025 ng/ml (group 2), safety margin test-
ing 0.094±0.051 ng/ml (group 3). Sample size was planned to obtain a power of 80% for rejec-
tion of the null hypotheses of no mean difference in hsTnT increase in pairwise group
comparisons assuming means and standard deviations for the groups as derived from the his-
torical data. Pairwise group comparisons using Welch’s t tests with an adjusted significance
ICD Shock Causes Elevation of hs-Troponin T
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level of α = 0.05/3 = 0.017 (Bonferroni correction) were planned assuming normally distrib-
uted hsTnT changes. Sample size calculation resulted in a total of 118 patients to be required
for the comparison of group 2 with group 1, a total of 28 patients for the evaluation of group 3
versus group 1, and a total of 46 patients for the comparison of group 3 and group 2. Taking
into consideration an attrition rate of 15% a total of 175 trial participants were planned to be
included in a 2:2:1 randomization scheme.
Data analysis was performed using the software packages SAS version 9.3 (SAS Institute
Inc., Cary, NC, USA) and R version 3.0.2 (R Foundation for Statistical Computing, Vienna,
Austria). The primary endpoint delta hsTnT was calculated as hsTnT after implantation minus
hsTnT before implantation. Analysis of the primary endpoint was carried using the full analy-
sis set (FAS), which was defined following the intention-to-treat principle. All patients with
valid hsTnT levels were included in the analysis and each patient was analysed in the group he
was randomized to irrespective of protocol deviations. Welch’s t-test with Satterthwaite’s
approximation for the degrees of freedom was used for pairwise group comparisons on an
adjusted level of significance of 0.017 to account for multiple group comparisons (Bonferroni-
adjustment). Accordingly, 98.3% confidence intervals for the differences of group means are
presented. The primary endpoint was additionally analysed in the per protocol population in
the sense of a sensitivity analysis.
Secondary endpoints were analysed in an explorative manner. For categorical outcomes
absolute and relative frequencies are presented and group comparisons were performed using
chi-squared tests. For quantitative measures means and standard deviations or medians and
ranges (minimum to maximum) are shown. Analysis of variance (ANOVA) was used to test
for equality of all group means for symmetrically distributed quantitative measures, Kruskal-
Wallis tests were performed for skewed data. Pairwise group comparisons were conducted
using t-tests or Mann-Whitney U tests, as appropriate. Spearman’s rank correlation coefficient




A total of 194 patients were included in three German centres between June 2010 and August
2012. Of these, 75 patients were randomized to “implantation of an ICD without intraoperative
ICD testing”, 79 patients to “implantation of the ICD with modified upper limit of vulnerability
testing” and 40 patients to “ICD implantation with induction of ventricular fibrillation and ter-
mination by ICD shock” (Fig 1). Baseline characteristics for the patients and the procedural
data are given in Tables 2 and 3 respectively. They did not differ significantly between the three
groups.
Primary endpoint
The primary analysis was performed in the full analysis set including 191 patients; three
patients were excluded due to missing hsTnT values for logistic reasons. The myocardial
micro-damage assessed by the delta hsTnT was 0.031±0.032 ng/ml in patients without intrao-
perative ICD-Testing, 0.080±0.067ng/ml in patients with ULV testing and 0.064±0.056ng/ml
in patients with safety margin testing. The change in hsTnT was significantly lower in the
group without intraoperative testing compared to the group with ULV testing (p<0.001, 98.3%
confidence interval for the difference in means [CI] 0.029 to 0.070) and also compared to the
group with safety margin testing (p = 0.001, 98.3% CI 0.010 to 0.057). However, delta hsTnT
did not differ significantly between the two groups with intraoperative ICD testing (p = 0.179,
ICD Shock Causes Elevation of hs-Troponin T
PLOS ONE | DOI:10.1371/journal.pone.0131570 July 24, 2015 6 / 15
98.3% CI -0.013 to 0.044) (Fig 2). Considering a slight deviation of the primary outcome mea-
sure from normal distribution, calculations have also been performed with a non-parametric
test showing no relevant impact on the significance level.
Secondary endpoints
In those patients from the full analysis set with valid CK measures (n = 190) the distribution of
delta CK-levels did not differ significantly between patients with intraoperative safety margin
testing (median 93U/l (minimum 7 U/l; maximum 1259 U/l)) and the group without such test-
ing (63U/l (-77 U/l; 1001 U/l); p = 0.067) nor was there a significant difference between the
group with ULV-testing (130U/l (-7 U/l; 516U/l)) and the group with safety margin testing
(p = 0.435). However, there was a significant difference in elevation of postoperative CK-levels
Fig 1. Consort Flow Diagram according to the CONSORT reporting guidelines.
doi:10.1371/journal.pone.0131570.g001
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between the group of patients with intraoperative ULV-testing and the group without such
testing (p = 0.003) (Fig 3).
Comparing the median delta CK-MB levels between the three groups of patients (n = 178)
there was no significant difference in the postoperative elevation of CK-MB levels compared to
the initial parameters, when the adjusted level of significance of 0.017 was used (1.2U/l (no test-
ing) vs. 3.0U/l (ULV) p = 0.025; 1.2U/l (no testing) vs. 1.9U/l (safety margin testing) p = 0.313;
3.0U/l (ULV) vs. 1.9U/l (safety margin testing), p = 0.439 (Fig 4).
Predictors of hsTnT release
Delta hsTnT was not associated significantly with the presence of an ischemic heart disease
(p = 0.991) nor did it correlate with the left ventricular ejection fraction (r = 0,110; p = 0.132).
There was a weak to moderate correlation between the elevation of hsTnT and the duration of
implantation (r = 0.357, p<0.001), the overall fluoroscopy time (r = 0.336, p<0.001) and the
number of lead fixations (r = 0.218, p = 0.002). Moreover, for the shock energy delivered on
the myocardium, a moderate correlation was observed (r = 0.333, p<0.001). Concerning pre-
operative creatinine and hsTnT levels, there was no correlation to changes in hsTnT demon-
strable (r = -0.108, p = 0.137 and r = -0.096, p = 0.188 respectively).





Upper limit of vulnerability





Age [years], mean ± SD 64.1±12.5 64.9 ± 13.0 63.7 ± 12.7 63.5 ± 11.4 0.777
Male gender n (%) 161 (83) 63 (84) 63 (80) 35 (88) 0.544
Ischemic cardiomyopathy n (%) 112 (58) 45 (60) 48 (61) 19 (48) 0.338
Dilated cardiomyopathy n (%) 78 (40) 28 (37) 29 (37) 21 (53) 0.217
Primary prevention n (%) 184 (95) 70 (93) 76 (96) 38 (95) 0.722
CRT n (%) 68 (35) 26 (35) 26 (33) 16 (40) 0.743
LV-EF [%], mean ± SD 28.7 ± 8.6 29.6 ± 9.4 28.9 ± 8.5 26.5 ± 6.7 0.185
Renal insufficiency n (%) 60 (31) 26 (35) 22 (28) 12 (30) 0.651
Creatinine [mg/dl]median (min-
max)
1.02 (0.44–4.52) 1.09 (0.50–2.91) 1.01 (0.60–4.52) 0.99 (0.44–2.03) 0.688




0.015 (0.003–0.351) 0.016 (0.003–0.712) 0.023 (0.003–0.136) 0.172
doi:10.1371/journal.pone.0131570.t002
Table 3. Procedural data.
Total number of










Subcutaneous position of ICD n (%) 143 (74) 58 (77) 53 (67) 32 (80) 0.211
Energy (J) Median (Min–Max) 52 (0–262) 0 (0–200) 62 (0–200) 62 (25–262) <0.001
Cut-to-suture time [min] Median (Min–
Max)
64 (17–338) 60 (20–222) 64 (17–338) 73 (25–256) 0.313
Fluoroscopy time [min] Median (Min–Max) 2.5 (0–40) 2.6 (0.2–30) 2.3 (0–37) 3.7 (0.1–40) 0.578
Contrast dye [ml] Median (Min–Max) 0 (0–350) 0 (0–350) 0 (0–120) 0 (0–250) 0.899
Intraoperative right ventricular electrode
positioning [n] median (Min-Max)
1 (1–11) 1 (1–11) 1 (1–9) 1 (1–8) 0.387
doi:10.1371/journal.pone.0131570.t003
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Per-protocol analysis
In 37 patients the study protocol could not be performed as intended; (no testing (group 1):
n = 10 (13%); ULV (group 2): n = 19 (24%); traditional safety margin testing (group 3): n = 8
(20%)). The main reasons for non-adherence to the protocol were as follows: in group 1 it was
the need for safety margin testing due to atypical lead locations (n = 4); in group 2 the reasons
were the need for safety margin testing (n = 1) or the unintended induction of VF (n = 13); in
group 3 the reasons were an increased DFT (n = 2) or the induction of an arrhythmia other
than ventricular fibrillation needing immediate cardioversion (n = 3) or hemodynamic deterio-
ration obviating repeated VF inductions (n = 2). The remaining 157 patients formed the cohort
of patients treated exactly according to the protocol.
For this cohort the per-protocol-analysis showed similar results as earlier described above
for the intention-to-treat population. There was a significant difference in delta hsTnT six
hours after implantation between the group of patients with intraoperative ICD testing and in
the group of patients without any testing (0.031±0.033ng/ml (no testing) vs. 0.084±0.071ng/ml
(ULV) p<0.001; 0.031±0.033ng/ml (no testing) vs. 0.064±0.060ng/ml (safety margin testing)
p = 0.007). Between the two patient groups with intraoperative ICD testing there was no signif-
icant difference in delta hsTnT levels (0.084±0.071ng/ml (ULV) vs. 0.064±0.060ng/ml (safety
margin testing), p = 0.155).
Fig 2. Primary endpoint; increase in hsTnT[ng/ml] (intention-to-treat) for all randomization groups. hsTnT = high sensitive Troponin T, No
Shock = Implantation without ICD testing, ULV = Upper Limit of Vulnerability Testing, VF = Induction of Ventricular Fibrillation (traditional safety margin
testing).
doi:10.1371/journal.pone.0131570.g002
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Discussion
Serum hsTnT levels in relation to the implantation of an ICD are poorly characterized. The
main findings of the randomized Trop-Shock-trial are: (1) The implantation of an ICD is asso-
ciated with an elevation of serum levels of hsTnT; (2) the study gives reference values of post-
operative hsTnT serum levels in relation to different strategies of DFT assessments (non-test-
ing strategy, testing with the mere application of shocks, traditional safety margin testing); (3)
there is no significant difference in the post-operative rise of hsTnT levels between a testing
strategy that applies shocks but aims to avoid the induction of ventricular fibrillation and the
traditional safety margin testing with the repeated induction of ventricular fibrillation followed
by defibrillation; (4) the post-operative release of hsTnT is significantly higher in patients with
intraoperative ICD testing than in patients without testing at all.
Our results confirm the observed post-procedural elevation of Troponin levels seen in previ-
ous studies [7–9, 18]. However, the available data only refer to Troponin T and Troponin I but
not to hsTnT which today is commonly used to assess myocardial micro-damage. In addition
to this, available data do not reflect different implantation or testing strategies [7–9]. By ran-
domizing patients to different intra-operative ICD testing strategies, individual reference values
for each of the testing approaches could be obtained. Post-operative hsTnT levels exceed the
reference value for serum hs TnT in a considerable number of patients (Table 2, Fig 2).
Fig 3. Secondary endpoint; increase in CK [U/l] (intention-to-treat) for all randomization groups.CK = Creatinkinase, No Shock = Implantation without
ICD testing, ULV = Upper Limit of Vulnerability Testing, VF = Induction of Ventricular Fibrillation (traditional safety margin testing).
doi:10.1371/journal.pone.0131570.g003
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Concerning the observed elevation of Troponin levels after ICD shocks, several authors
posed the question whether they were related to cardiac arrhythmias or the ICD shock itself
[7–8, 10]. This issue has recently been addressed indirectly in an observational study which
found elevated troponin levels after inappropriate shocks due to lead failure in otherwise
healthy and hemodynamically stable patients [19]. By randomly assigning patients to receive
shocks without preceding arrhythmias or to receive shocks to terminate induced ventricular
fibrillation, we aimed to more precisely determine the source of myocardial micro-damage.
Applying the same amount of energy to the myocardium, there was no statistically significant
difference in hsTnT rise between the two groups with shock applications. Thus, we deem that
the application of a shock but not the underlying ventricular arrhythmia causes the hsTnT ele-
vation. In this context, electroporation known as an electrically induced dysfunction of myo-
cytes due to transient enhancement of myocyte membrane permeability and disturbed
myocyte calcium homeostasis might be of relevance [12,20]. Additionally, damage to the cell
membrane due to micro infarction, inflammation or cellular apoptosis may play a role in
shock-associated Troponin release [10].
The least rise in post-operative hsTnT levels was observed in the non-testing group which
was statistically significantly lower when compared to each of the two groups receiving testing
strategies with the application of shocks. This result is in contrast to a recent report by Furniss
Fig 4. Secondary endpoint; increase in CK-MB[U/l] (intention-to-treat) for all randomization groups.CK-MB = Creatinkinase MB, No
Shock = Implantation without ICD testing, ULV = Upper Limit of Vulnerability Testing, VF = Induction of Ventricular Fibrillation (traditional safety margin
testing).
doi:10.1371/journal.pone.0131570.g004
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et al. which suggests that elevation of post-operative hsTnT levels are caused by the implanta-
tion and are not enhanced by defibrillation threshold testing [21]. However, the aforemen-
tioned study is limited by a small number of included patients and by its non-randomized
nature. We therefore believe that minimizing implantation-related myocardial micro-damage
is best to be achieved by avoiding shock applications.
Keeping the Troponin release during ICD implantation as low as possible seems to be an
intuitive strategy. Such a strategy may be applicable to all ICD recipients as there was no signif-
icant correlation between Troponin release and left ventricular ejection fraction or underlying
cardiac disease (ischemic versus non-ischemic) in our trial. However, it is unclear whether a
lowering of post-operative Troponin levels translates into a favourable long-term outcome of
the patients. Therefore, our study cannot give a definitive advice on whether or not to perform
ICD testing at implantation. On the one hand, the magnitude of Troponin release has been
linked to the patient´s short- and long-term outcome in several clinical circumstances [22–25]
and augmented Troponin levels after cardioversion or defibrillation of ventricular tachyar-
rhythmias have been reported to be associated with increased mortality [10]. On the other
hand, these correlations may not necessarily be transferable to the specific setting of elevated
hsTnT levels measured after ICD implantation. When randomizing patients to an ICD implan-
tation with or without defibrillation threshold testing, the recent large scale SIMPLE study
showed no significant differences between first shock efficacy and mortality in the long run
[26]. These results confirmed the observations of the non-randomized SAFE-ICD-Trial [27].
The ongoing NORDIC trial with a similar design may give further insight into the prognosis of
patients with or without ICD testing at implantation [28].
Supported by technical improvements of the recent years (e. g. availability of high and ultra-
high energy devices, painfree measurements of shock impedance, programmable alternating
shock polarity, programming strategies to avoid shocks which make patients less dependent on
shocks) these studies may enhance the trend towards a non-testing implantation strategy [29].
Our finding of a significantly larger increase in hsTnT release in the testing groups compared
to the non-testing group may provide proponents for a simplified implantation procedure with
additional arguments in favour of the discontinuation of routine ICD testing. Currently, the
perceptions whether or not to induce ventricular arrhythmias during ICD implantations varies
significantly between implanters resulting in different testing strategies and it is anticipated
that these divergent practices may only be harmonised after the publication of a consensus
statement by the relevant cardiac societies.
Because our trial was designed as an acute study we are not able to conclude on potential
long-term adverse effects related to hsTnT release during the ICD implantation procedure.
However, our study shows that the ICD shock, not ventricular fibrillation, causes the elevation
of hsTnT after defibrillation threshold testing at implantation. When balancing risks and bene-
fits of intraoperative ICD function testing, the myocardial micro-damage inherent to ICD
shocks should be considered.
Limitations
The study was designed to determine myocardial damage in relation to different implantation
strategies and aimed to determine whether lead placement, arrhythmia induction or the appli-
cation of shocks contribute most to a potential myocardial micro-damage. For this, the study
protocol was optimized to apply the same cumulative shock energies in the two groups with
shock applications. Therefore it was not possible to assess a potential influence of different
cumulative shock energies on myocardial damage.
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In order to avoid a potential bias in myocardial damage caused by different lead types, only
standard active fixation leads were used in the study. It is assumed that this has not influenced
the study results in respect to arrhythmia induction or shock application. However, we cannot
conclude on the potential differences in myocardial micro-damage related to active versus pas-
sive fixation leads and given reference values only refer to active fixation leads.
As the study aimed to characterize the acute effect of different implantation strategies on
myocardial damage, no conclusion can be made on a potential long-term impact.
Conclusion
Myocardial micro-damage assessed by hsTnT is significantly higher in patients with intra-
operative defibrillation threshold testing compared to those without testing. Shock applica-
tions, with or without arrhythmia induction, did not result in a significantly different increase
in hsTnT. Therefore, the ICD shock itself and not ventricular fibrillation seems to cause myo-
cardial micro-damage.
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